What is BNTC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.31B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BNTC?

P/E (TTM) is n/a and 52-week range is $8.52 to $16.76 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BNTC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BNTC?

The company profile lists revenue (TTM) near $70K, net income (TTM) near $-1.45B, EPS (TTM) near $-1.11 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Benitec Biopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Hayward, California, US, 34.4M shares outstanding, ISIN US08205P2092 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Benitec Biopharma Inc

$BNTC

Health Care · Biotechnology

IR Run Scenarios

$8.87

+1.37%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 19 full-time employees. The company went IPO on 2012-07-11. The firm is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The firm is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

Employees

Website

benitec.com/

IPO

2012-07-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)